2.94
price up icon0.00%   0.00
after-market Dopo l'orario di chiusura: 2.96 0.02 +0.68%
loading
Precedente Chiudi:
$2.94
Aprire:
$2.96
Volume 24 ore:
2.89M
Relative Volume:
0.82
Capitalizzazione di mercato:
$631.11M
Reddito:
$12.87M
Utile/perdita netta:
$-114.34M
Rapporto P/E:
-3.4004
EPS:
-0.8646
Flusso di cassa netto:
$-79.23M
1 W Prestazione:
+8.09%
1M Prestazione:
+17.13%
6M Prestazione:
+80.37%
1 anno Prestazione:
+28.38%
Intervallo 1D:
Value
$2.85
$2.99
Intervallo di 1 settimana:
Value
$2.685
$3.12
Portata 52W:
Value
$1.05
$3.31

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name
Nome
Taysha Gene Therapies Inc
Name
Telefono
(214) 612-0000
Name
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Name
Dipendente
73
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
TSHA's Discussions on Twitter

Confronta TSHA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TSHA
Taysha Gene Therapies Inc
2.94 802.02M 12.87M -114.34M -79.23M -0.8646
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
392.79 100.07B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
580.41 59.99B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
448.91 58.03B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
653.83 39.93B 3.06B 1.28B -614.78M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
321.36 36.82B 3.81B -644.79M -669.77M -6.24

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-11 Iniziato BofA Securities Buy
2024-06-27 Iniziato BMO Capital Markets Outperform
2024-04-09 Iniziato Piper Sandler Overweight
2023-02-01 Downgrade Jefferies Buy → Hold
2023-01-27 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-11-09 Downgrade Goldman Buy → Neutral
2022-03-09 Iniziato Robert W. Baird Outperform
2022-03-01 Iniziato Wells Fargo Overweight
2022-02-18 Iniziato SMBC Nikko Outperform
2021-12-16 Iniziato Guggenheim Buy
2021-07-16 Iniziato Needham Buy
2021-06-24 Iniziato Truist Buy
2021-06-15 Iniziato BTIG Research Buy
2021-06-09 Iniziato Wedbush Outperform
2021-06-08 Iniziato JMP Securities Mkt Outperform
2021-05-19 Iniziato Cantor Fitzgerald Overweight
2021-05-11 Ripresa Jefferies Buy
2021-02-24 Iniziato William Blair Outperform
2021-01-05 Iniziato Oppenheimer Outperform
2020-10-19 Iniziato Chardan Capital Markets Buy
2020-10-19 Iniziato Goldman Buy
2020-10-19 Iniziato Jefferies Buy
2020-10-19 Iniziato Morgan Stanley Overweight
Mostra tutto

Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie

pulisher
08:30 AM

BofA Securities Affirms ‘Buy’ Rating on Taysha Gene Therapies (TSHA) on TSHA-102 Prospects - MSN

08:30 AM
pulisher
Aug 14, 2025

Taysha Gene Therapies Inc. Consolidation Zone May Signal Accumulation2025 Fundamental Recap & Real-Time Volume Analysis Alerts - metal.it

Aug 14, 2025
pulisher
Aug 14, 2025

Taysha Gene Therapies’ SWOT analysis: promising Rett syndrome treatment boosts stock outlook - Investing.com

Aug 14, 2025
pulisher
Aug 13, 2025

Taysha Gene Therapies price target raised to $14 from $11 at Canaccord - MSN

Aug 13, 2025
pulisher
Aug 13, 2025

Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA) - The Globe and Mail

Aug 13, 2025
pulisher
Aug 13, 2025

A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $8 to $14 - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 13, 2025
pulisher
Aug 13, 2025

Canaccord Genuity raises Taysha Gene Therapies stock price target on pivotal study progress By Investing.com - Investing.com South Africa

Aug 13, 2025
pulisher
Aug 13, 2025

Canaccord Genuity raises Taysha Gene Therapies stock price target on pivotal study progress - Investing.com UK

Aug 13, 2025
pulisher
Aug 13, 2025

Taysha plans pivotal TSHA-102 trial enrollment in Q4 2025, extends cash runway to 2028 - MSN

Aug 13, 2025
pulisher
Aug 13, 2025

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates - MSN

Aug 13, 2025
pulisher
Aug 13, 2025

Taysha Gene 2025 Q2 Earnings Significant Revenue Growth Despite Worsening Net Loss - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ... - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

Taysha Gene Therapies Advances Rett Syndrome Trials - TipRanks

Aug 13, 2025
pulisher
Aug 12, 2025

Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Aug 12, 2025
pulisher
Aug 12, 2025

Chardan Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $10 - 富途牛牛

Aug 12, 2025
pulisher
Aug 12, 2025

Chardan Capital Keeps Buy Rating on Taysha Gene with PT Raised to $10 - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Taysha Gene Therapies shares rise 6.70% intraday after reporting Q2 2025 earnings. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Transcript : Taysha Gene Therapies, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener

Aug 12, 2025
pulisher
Aug 12, 2025

Taysha Gene Therapies' Q2 2025: Key Contradictions in Clinical Trial Endpoints and Regulatory Strategy - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Taysha Gene Therapies, Inc. SEC 10-Q Report - TradingView

Aug 12, 2025
pulisher
Aug 12, 2025

Earnings call transcript: Taysha Gene’s Q2 2025 revenue beats forecast - Investing.com

Aug 12, 2025
pulisher
Aug 12, 2025

TSHATaysha Gene Therapies, Inc. Latest Stock News & Market Updates - Stock Titan

Aug 12, 2025
pulisher
Aug 12, 2025

Is Taysha Gene Therapies Inc. benefiting from interest rate changesSteady Performer Watchlist - mustnews.co.kr

Aug 12, 2025
pulisher
Aug 12, 2025

How does Taysha Gene Therapies Inc. perform in inflationary periodsBest Picks for Wealth Multiplication - newsyoung.net

Aug 12, 2025
pulisher
Aug 12, 2025

Taysha Gene Therapies Inc. Reaches Critical Trendline SupportAlpha Focused Technical Trade Signals Gain Attention - beatles.ru

Aug 12, 2025
pulisher
Aug 12, 2025

Podcast: Astellas SVP On Doubling Down On Gene Therapy Despite Industry Headwinds - insights.citeline.com

Aug 12, 2025
pulisher
Aug 09, 2025

Taysha Gene TSHA Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships and Innovation - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Wells Fargo Remains Bullish on Taysha Gene Therapies (TSHA) - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Taysha Gene Therapies Inc. Breaks Losing Streak — Is the Trend ReversingPortfolio Diversification Stock Ideas From Experts - beatles.ru

Aug 09, 2025
pulisher
Aug 08, 2025

Taysha Gene Therapies Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Aug 08, 2025
pulisher
Aug 06, 2025

Earnings Preview: TSHA to Report Financial Results Pre-market on August 12 - 富途牛牛

Aug 06, 2025
pulisher
Aug 06, 2025

Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 - 富途牛牛

Aug 06, 2025
pulisher
Aug 05, 2025

Taysha Gene Therapies to Release Second Quarter 2025 - GlobeNewswire

Aug 05, 2025
pulisher
Aug 04, 2025

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know - Yahoo Finance

Aug 04, 2025
pulisher
Aug 04, 2025

RSI Crosses Above 30 for Taysha Gene Therapies Inc. — Reversal in SightCommunity Shared Smart Money Signals Show Movement - beatles.ru

Aug 04, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Taysha Gene Therapies Inc. in the next 12 monthsDiscover undervalued stocks before they soar - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are Taysha Gene Therapies Inc. company’s key revenue driversBuild wealth with steady, reliable stocks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How many analysts rate Taysha Gene Therapies Inc. as a “Buy”Maximize gains with data-driven stock picks - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What analysts say about Taysha Gene Therapies Inc. stockSuperior trading gains - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

10 Best Strong Buy Penny Stocks to Buy Now - Insider Monkey

Aug 03, 2025
pulisher
Aug 03, 2025

What is Taysha Gene Therapies Inc. company’s growth strategyTriple returns potential - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Taysha Gene Therapies Inc. stock overvalued or undervaluedUnlock real-time stock alerts for quick profits - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Taysha Gene Therapies Inc. generate profit in a changing economyFree Trend-Following Techniques - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Taysha Gene Therapies Inc.Maximize returns with strategic trading plans - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the technical indicators suggesting about Taysha Gene Therapies Inc.Achieve triple-digit returns with smart investing - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What makes Taysha Gene Therapies Inc. stock price move sharplyAchieve breakthrough financial growth - jammulinksnews.com

Aug 02, 2025
pulisher
Aug 02, 2025

Taysha Gene Therapies Announces New Employee Stock Option Grant Under Nasdaq Listing Rule 5635(c)(4) - AInvest

Aug 02, 2025
pulisher
Aug 02, 2025

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - MSN

Aug 02, 2025
pulisher
Aug 01, 2025

What is the risk reward ratio of investing in Taysha Gene Therapies Inc. stockDaily Trading Opportunities For Fast Growth - Jammu Links News

Aug 01, 2025
pulisher
Aug 01, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Aug 01, 2025

Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$36.35
price down icon 0.41%
$86.92
price up icon 0.88%
$26.69
price up icon 0.91%
$127.80
price up icon 0.04%
$113.52
price up icon 0.73%
biotechnology ONC
$321.36
price up icon 3.77%
Capitalizzazione:     |  Volume (24 ore):